key: cord-0712700-zmcc32yo
authors: Hennon, Teresa R.; Yu, Karl O.A.; Penque, Michelle D.; Abdul-Aziz, Rabheh; Chang, Arthur C.; McGreevy, Megan B.; Pastore, John V.; Prout, Andrew J.; Schaefer, Beverly A.; Alibrahim, Omar S.; Gomez-Duarte, Oscar G.; Hicar, Mark D.
title: COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; revisiting the Western New York approach as the pandemic evolves
date: 2021-06-06
journal: Prog Pediatr Cardiol
DOI: 10.1016/j.ppedcard.2021.101407
sha: d2cf7a127133178e2f232830f42396e1b4403ad7
doc_id: 712700
cord_uid: zmcc32yo

Multisystem inflammatory syndrome of children (MIS-C) continues to be a highly concerning diagnosis in those recently infected with SARS-CoV-2. The diagnosis of MIS-C cases will likely become even more challenging as vaccine uptake and natural immunity in previously infected persons leads to lower circulating rates of SARS-CoV-2 infection and will make cases sporadic. Febrile children presenting with cardiac dysfunction, symptoms overlapping Kawasaki disease or significant gastrointestinal complaints warrant a thorough screen in emergency departments, urgent care centers, and outpatient pediatric or family medicine practices. An increased index of suspicion and discussion regarding higher level of care (transferring to pediatric tertiary care centers or to intensive care) continue to be recommended. Herein we outline a broad approach with a multidisciplinary team for those meeting the case definition, and believe such an approach is crucial for successful outcomes.

tumor necrosis factor (TNF) [18, 19] . A recent study comparing children with severe acute COVID-19 infection to those with MIS-C showed MIS-C patients were more likely to be age 6 -12 years, non-Hispanic Black, and have more significant cardiovascular and mucocutaneous inflammation. [20] . MIS-C was also independently associated with lower socioeconomic background, Hispanic ethnicity, and Black race [21] .

The cumulative MIS-C incidence in persons younger than 21 years is 2 per 100,000, with cases following acute infections by an average of 2 -5 weeks [2] . The CDC has an updated website on clinical information regarding MIS-C [22] . Over 3700 cases have been reported with a near 1% mortality rate and 99% with positive testing (by nucleic acid, antigen, and/or antibody) for SARS-CoV-2. The cases have a median age of 9 years (range <1 -20) and are predominantly 1 -14 years of age. 63% of reported cases have occurred in children who are Hispanic/Latino or non-Hispanic Black. More than half (59%) of reported cases are male.

Reports have emerged from young adults with similar presentations, a syndrome termed MIS-A (Adult) [23, 24] . Generally, acute COVID-19 has distinct clinical signs and symptoms and laboratory findings [25] , but some acute respiratory COVID-19 presentations may fulfill MIS-C criteria [9, 26] . Interestingly, younger children with MIS-C are more likely than adolescents to be SARS-CoV-2 IgG positive (86% for cases 0 -9 years of age versus 70% for 15 -20 years), whereas the opposite is seen for polymerase chain reaction (PCR)-positivity (48% versus 64%, respectively) [2] . The age group most affected by MIS-C are those for which COVID-19 vaccines are not yet available for SARS-CoV-2 infection prevention.

The CDC definition of multisystem involvement includes ≥ 2 organ systems. The level of dysfunction that qualifies for a system to be included for MIS-C has not been specifically defined [27] , but reports are consistent with organ dysfunction defined in guidelines for severe Primary respiratory complaints can be seen in MIS-C. A number of cases of MIS-C are PCR-positive and have pulmonary involvement, including chest X-ray infiltrates. In MIS-C, GI complaints can be so severe, that patients may be suspected as having a surgical abdomen (e.g., potential appendicitis) prompting evaluation from a surgeon [42] . Patients in whom there is a low index of suspicion but present with some features of MIS-C should be considered for screening for inflammation with a complete metabolic panel, complete blood count with differential, sedimentation rate (ESR) and CRP.

Timely SARS-CoV-2 nasopharyngeal PCR and antibody testing should be done, both for diagnostic and infection control purposes. With continued evolution of the pandemic, genetic variants may influence the diagnostic accuracy of certain tests. Interpretation of results will depend on several factors including the type of antibody testing locally performed, country of residence, recent travel history, known exposures, and specific SARS-CoV-2 vaccine formulation if obtained. The nucleoprotein (NP) is the antigen used in many commercial antibody assays. Antibodies against NP can distinguish natural infection from vaccination for those vaccines that produce or contain Spike or receptor binding domain (RBD) antigens (Table   1 ) [43] [44] [45] . There are assays available that measure antibodies against SARS-CoV-2 Spike protein or the RBD, but these would not distinguish natural infection from vaccination [46, 47] .

This differentiation by antibodies against NP is not applicable for the inactivated whole viral vaccines ( Table 1 ) so interpretation of antibody testing in a patient who received these types of vaccines will be difficult [48] . It is anticipated that more vaccines using a variety of platforms with presentation of a variety of antigens will be approved. Clinicians should keep current on vaccine developments, testing available at their institution, and effects of viral variants currently circulating, to assist in interpretation of viral testing.

Patients with signs and symptoms fulfilling the case definition of MIS-C (see Figure 1) should undergo a more extensive workup. Discussion with local pediatric emergency medicine or infectious disease physicians that serve one's area is encouraged for further guidance on the workup of suspected cases.

Published reports and our own experience show that patients can initially be wellappearing with reassuring laboratory workup, only to return to the hospital days later with worsening symptoms and rapid clinical deterioration [32] . We propose that the patients evaluated for this condition who are discharged from the emergency department are given MIS-C specific discharge instructions and have a follow-up clinic or telehealth visit (as well as a repeat of their MIS-C screening labs if their symptoms continue) within 24 -72 hours. Since a broad differential of infections can have overlapping manifestations, direct follow-up or discussion with local pediatric infectious disease physicians for questions that may arise during follow-up is recommended.

Proposing detailed criteria for hospital admission is challenging and it will depend on multiple factors. In some children, a rapid decline in clinical status can occur [32] . Children suspected to have MIS-C that are initially being evaluated in a rural area or a local emergency department/urgent care center/hospital, should be stabilized and transferred as quickly and safely as possible to a tertiary medical center. From our own experience and in published studies [31] , there appear to be mild forms of this condition without cardiac involvement and with only mild laboratory abnormalities. These may resolve without medical intervention. It is unclear if the recognition of milder cases is from lack of initial reporting of such cases, change in the circulating strains, epidemiologic changes in groups affected, or from improvements in clinical J o u r n a l P r e -p r o o f care. Our center has been aggressive in our treatment strategy; we suspect this may be one possible explanation for relative lack of severe outcomes in our cohort.

The multi-faceted nature of the disease course and various presentations underlines the need for multispecialty input and coordination of care. As a subset of children can become severely ill quickly, referral to a tertiary care center is paramount. Pediatric infectious diseases should be consulted early on in all cases being considered for MIS-C, as bacterial and viral illness may present similarly. Pediatric rheumatology, if available, should be involved early, especially in cases with high clinical suspicion. Critical care is consulted as needed and, in our center, often informed of mild cases since care needs can change quickly. We recommend pediatric cardiology consultation if there are abnormalities in BNP or troponin levels, or on electrocardiogram (EKG) or echocardiogram. As the name implies, the multisystem inflammation seen in these cases may require seeking input from other subspecialties (pediatric neurology, gastroenterology, hematology, or surgery) as the need arises.

MIS-C presentation among children admitted to the hospital fall under three distinctive categories for the purposes of treatment recommendations: i) MIS-C with features of acute COVID-19; ii) MIS-C with predominant KD features; and iii) MIS-C with shock, myocarditis or severe multisystem involvement. Children presenting with shock frequently require cardiac and respiratory support. Generally, antibiotic coverage should be empiric in patients diagnosed and/or hospitalized with MIS-C, with initial broad-spectrum antibiotics recommended as symptoms may overlap with severe bacterial infections. For patients with milder illness, we suggest ceftriaxone if there is concern for coinfection. As GI symptoms are a common J o u r n a l P r e -p r o o f presentation of MIS-C, addition of metronidazole may be considered in cases where ileitis or colitis is seen on imaging. In cases of severe illness or shock, we advise empiric coverage that targets methicillin-resistant Staphylococcus aureus, resistant Gram-negatives, and includes antibiotics that inhibit toxin production since toxic shock will be in the differential diagnoses.

We often use vancomycin, cefepime, and clindamycin or vancomycin, meropenem, and gentamicin. We strongly encourage consultation with local pediatric infectious disease experts prior to transfer of care or quickly after initial evaluation (see Figure 1) .

The antiviral drug remdesivir should be considered for those known to be PCR-positive and/or with a presentation consistent with typical COVID-19. This should be guided by a pediatric infectious disease consultant and by current treatment guidelines. In particular, remdesivir is recommended in COVID-19 patients requiring supplemental oxygen, or oxygen through a high-flow device or non-invasive ventilation, but not in patients needing invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). Remdesivir is not recommended in patients with abnormal liver function or severe renal compromise. For children under twelve years old, remdesivir has a U.S. Food and Drug Authority (FDA) emergency use authorization. The current remdesivir dosing for children is 5 mg/kg load IV (maximum 200 mg) on day 1, then 2.5 mg/kg (maximum 100 mg) IV daily for 4 -9 days. There does not appear to be a role for convalescent serum or recombinant antibodies for these presentations, even for patients presenting with acute SARS-CoV-2 [49] .

A number of adjunct therapies have been used because of the profound inflammatory response and KD-like features, although few studies support their use. Many centers have treated children that present most similarly to KD with traditional therapy used for KD, as detailed in recent guidelines [35] . For those who qualify as a case of KD, including concern for coronary J o u r n a l P r e -p r o o f artery involvement on echocardiogram, we recommend giving IV immunoglobulin G (IVIG) 2 g/kg and oral high dose aspirin 20 -25 mg/kg/dose every 6 hours (80 -100 mg/kg/day) until the fever resolves. Daily low dose aspirin 3 -5 mg/kg/day (maximum 81 mg) is then prescribed after initial improvement, and maintained until coronary arteries are assessed during outpatient follow-up with pediatric cardiology. Acute aspirin dosage may also vary at individual centers.

Recent data from a retrospective review supports the use of corticosteroids in MIS-C cases [50] . Patients treated with IVIG alone were compared to IVIG and methylprednisolone.

Most cases received 0.8 to 1 mg/kg (maximum 30 mg) methylprednisolone every 12 hours for 5 days, while the remaining children received a bolus of 15 to 30 mg/kg/day of methylprednisolone for 3 days. All primary (fever) and secondary endpoints (additional therapy, hemodynamic support, left ventricular dysfunction, and length of pediatric intensive care unit stay) favored inclusion of corticosteroids. Initiation of three-day pulse methylprednisolone with the initial IVIG infusion for children with KD can be considered for children at high risk (infants, KD shock syndrome, CRP > 130 mg/L, admission echo Z score > 2.5 or aneurysms, and Asian race).

Current data supports the use of both IVIG and corticosteroids in all three categories of MIS-C. Dexamethasone has been used as an adjunctive treatment for hospitalized patients with active COVID-19 infection with prominent respiratory features and/or shock; however, methylprednisolone is more commonly used for MIS-C. A recently-published randomized controlled trial and retrospective trials suggest superiority of methylprednisolone over dexamethasone for acute/respiratory COVID-19 [51, 52] . We would recommend use of methylprednisolone in all cases of MIS-C, unless there is a high index of suspicion for concomitant infection or if steroids are contraindicated.

Many centers, including ours, will use the IL-1 receptor antagonist anakinra if additional immune modulation is required. However, no formal studies support or refute this approach [53] . If the clinical presentation is most consistent with KD, and there is failure of first line treatment, a second dose of IVIG or infliximab (a TNF-α inhibitor) could be considered, per KD guidelines [35] . Other immunomodulators are not recommended [27] , but can be used if a patient is refractory to optimized methylprednisolone, anakinra, and IVIG treatment. In our experience, early initiation of aggressive treatment has led to short hospitalization time, minimal organ damage, and good short-and long-term outcomes (see Rheumatology section for details).

Gastrointestinal presentation and findings MIS-C frequently presents with prominent gastrointestinal (GI) signs and symptoms (70-90% of reported cases) [9-11, [13] [14] [15] [16] [17] including abdominal pain, diarrhea, nausea, vomiting, constipation, and GI bleeding [54, 55] . GI manifestations are not surprising since enterocytes, including those lining the appendix, are rich in angiotensin-converting enzyme 2 (ACE2), the receptor used by SARS-CoV-2 [56] . GI manifestations in MIS-C may be severe and prompt surgical intervention. Appendicitis has been described in PCR-negative/antibody-positive case reports [57, 58] and a case series where all were PCR-positive but had other characteristics consistent with MIS-C [42] . The clinical presentation may also resemble inflammatory bowel disease and include severe abdominal pain and GI bleeding [54, 55] . GI symptoms may initially be mild before progressing to signs of acute abdomen [59, 60] . Cases presenting with severe abdominal pain or evidence of GI bleed must be approached cautiously, as cases of unrelated isolated acute appendicitis may also appear to be MIS-C at first glance [61] and a number of children with bacterial gastroenteritis due to Campylobacter or Salmonella have been J o u r n a l P r e -p r o o f misdiagnosed as MIS-C [62] . In addition to bowel pathology, acute hepatitis has also been reported in MIS-C. In the majority of cases, acute hepatitis is associated with severe disease, including shock, and it may be a secondary severe MIS-C rather than a primary MIS-C hepatic disorder [63] .

For those with significant GI manifestations, testing beyond "Set 1" labs (Figure 1) should include pancreatic enzymes and specific imaging. A plain abdominal X-ray can evaluate for signs of perforation, and abdominal CT will be helpful for acute abdomen presentations due to inflammatory bowel disease-like disorder, appendicitis, or bowel perforation. Pediatric GI and/or surgical consultation is critical to address appropriate evaluation, as well as medical and/or surgical treatment.

Prior to the COVID-19 pandemic, it was very uncommon for children presenting with In children presenting with shock (most have reported vasodilatory shock), fluid resuscitation is imperative in the initial management. As there is a high potential for underlying cardiac dysfunction, patients should be frequently reassessed during fluid resuscitation for J o u r n a l P r e -p r o o f evidence of fluid overload, such as pulmonary edema or hepatomegaly. In centers with bedside ultrasound available, evaluation of cardiac function may be considered early in resuscitation to determine best management. Complete transthoracic echocardiograms should be performed urgently in all patients with clinical or laboratory evidence of cardiac injury and/or shock (see Figure 1 ). In children with reassuring initial cardiac evaluation or mild to moderate disease, it is reasonable to consider ongoing cardiac screening throughout hospitalization due to reports of rapid decompensation. It is also reasonable to follow serum troponin and/or BNP levels and consider repeating echocardiograms in children with significant laboratory or clinical changes.

All children with MIS-C should have outpatient follow-up with pediatric cardiology. We recommend follow-up about one month after diagnosis for children without evidence of cardiac involvement during their hospital course. Closer follow-up is needed for children with myocardial involvement. Recommendations from the American Academy of Pediatrics is to treat all children with MIS-C similarly to children who have had viral myocarditis [65] . This includes exercise restriction for 3 -6 months and obtaining specific cardiology clearance prior to resuming training or competition. During those visits, repeat cardiologic testing may include electrocardiogram, cardiac MRI, and stress testing to evaluate for any evidence of myocardial injury or scarring depending on the individual case and available testing modalities.

Critical care evaluation and management is warranted in most cases [10, 11, 37, 66] . 67, 68] . This initial approach combined with multidisciplinary management and initiation of early but comprehensive diagnostics help to guide further therapeutic choices (e.g., antithrombotic agents, antibiotics, and immune modulating medications). There is an increasing recognition of neurological manifestations including seizure, headache, meningitis, encephalopathy, muscle weakness, brain stem and cerebellar signs that also support critical care involvement [69] . This study described the experience of 35 critically ill children with MIS-C presenting with acute myocardial injury/myocarditis and cardiogenic shock. Initial symptoms on presentation were mainly fever, fatigue and GI manifestations. Inotropic support was required in 80% of cases, while veno-arterial (VA) ECMO was initiated in 28% in this cohort. Despite the rapid deterioration at presentation, a rapid resolution of the systolic myocardial function was noted.

All patients survived and none had embolic or thrombotic events. All patients received IVIG and 65% received heparin for anticoagulation. Patients with this severity of decompensation should be considered for aggressive immunomodulation and antithrombotic management, as these interventions have clinically been shown to alter the course of these patients rapidly. 

and MIS-C vary institutionally, but many have elected for a minimum prophylactic anticoagulation strategy in adolescents and the critically ill. Expert consensus guidelines [73] support prophylactic anticoagulation for pediatric patients with COVID or MIS-C who have elevated D-dimer levels > five times the upper limit of normal, age above twelve years, or with risk factors including a central line, mechanical ventilation, obesity, hospital stay > three days, immobility, active malignancy, nephrotic syndrome, cystic fibrosis exacerbation, sickle cell J o u r n a l P r e -p r o o f exacerbation, inflammatory disease (e.g., lupus, juvenile idiopathic arthritis, inflammatory bowel disease) with exacerbation, congenital/acquired cardiac disease with impaired venous return, or a personal or first-degree relative with a history of VTE, known thrombophilia and others.

Decisions regarding post-hospital discharge prophylaxis should be individualized and considered for patients with existing risk factors (as above), an elevated D-dimer on discharge, or those who have not returned to previous level of functioning. Patients with expanding or large coronary artery aneurysms will require therapeutic anticoagulation and antiplatelet therapy, following established guidelines for KD [35] . The effect of these interventions in ameliorating disease severity needs further study. Coagulopathy and cytopenias are also observed with MIS-C. In critically-ill adults with acute COVID, bleeding complications have become increasingly recognized [75] . Other postinfectious complications including the development of autoimmune hemolytic anemias (warm, cold, direct antiglobulin test-negative, or cold agglutinin disease), immune thrombocytopenia, autoimmune thrombotic thrombocytopenia purpura have also been observed [76] .

Sepsis and/or toxic shock should be considered and addressed in all cases presenting with cardiovascular compromise, and empiric antibiotics are recommended as previously detailed (see We agree with a stepwise approach to treatment for hospitalized patients. We suggest patients that meet MIS-C criteria and are admitted to the hospital receive IVIG 2 g/kg as a first . Due to the medication volume, patients with cardiac dysfunction will need to be monitored more closely during and after infusion, and consideration given to split the dose to 1 g/kg/day over 2 days. We also suggest that corticosteroids be given as an adjunctive therapy.

Methylprednisolone IV (2 -30 mg/kg/day, max 1 gram) is preferred and used most often on presentation and doses will depend on severity of disease. Once a patient improves and can tolerate PO this can be switched to an oral form of prednisone (1-2 mg/kg/day, max 60 mg). This approach is supported by a recent study from France that showed that combined treatment with IVIG and steroids led to a lower risk of treatment failure [50] . Classifying patients in terms of severity of disease has proven difficult and subjective based on the evaluating clinician, the timing of the evaluation (as changes can occur rapidly within hours and daily), and timing of treatments given. It is reasonable to give IVIG and corticosteroids soon after diagnosis and reassess if higher doses of steroids are needed, or if anakinra needs to be added to the regimen.

We propose the use of IVIG, high-dose corticosteroids and anakinra as early as possible among patients with shock, cardiac dysfunction or evidence of other severe organ dysfunction or respiratory failure. This approach in our center has anecdotally led to relatively short hospitalizations, and good overall outcomes.

Anakinra, a recombinant human IL-1 receptor antagonist, has a quick onset, a short halflife (4 hours), a large therapeutic window, and a good safety profile [78] . Dosing ranges from 2 -20 mg/kg/day, depending on severity of disease [27] . This can be considered as first-line treatment for patients with severe disease, or added to patients that are refractory to use of IVIG and/or corticosteroids, or to those with contraindication to use of corticosteroids. IL-1 blocking agents are FDA approved for several autoinflammatory syndromes and systemic onset juvenile J o u r n a l P r e -p r o o f Journal Pre-proof idiopathic arthritis [79] and they have an excellent safety profile [78, [80] [81] [82] . As with any immune modulating agent, the main risk is infection. However, with its short half-life, anakinra may be discontinued and its effects short lived if a concurrent infection is found, or if the clinical condition worsens. There are case descriptions of anakinra use in a small number of MIS-C patients and anakinra has been used successfully in a small number of patients with IVIGresistant KD [83] [84] [85] . Children with MIS-C require a prolonged course of corticosteroids to avoid rebound inflammation. Once afebrile and stable in the hospital and medication is changed to oral form, the doses can be tapered most often over a 2 -3 week time period.

The hospital course can be highly variable. We recommend daily clinical and laboratory evaluation be done on all hospitalized children depending on the disease classification (see Figure 1 ). We advise stopping antibiotics after 48 hours unless bacteremia is diagnosed, or localized secondary infection is suspected. Children should be continuously monitored for fevers or evidence of ongoing or increasing inflammation. If clinical inflammation continues or worsens, retreatment or alternative therapy should be considered, as guided by infectious diseases and rheumatology. Aspirin dosing is similar to American College of Rheumatology MIS-C guidelines [27] . All children with MIS-C receive daily low-dose aspirin. Our center will hold on aspirin for children with thrombocytopenia until platelets are near normalization. If highdose aspirin was begun due to presentation similar to KD, our center decreases aspirin dosing to 3 -5 mg/kg daily once the child is afebrile for more than 24 hours. This will continue after discharge until follow-up with pediatric cardiology.

To confirm clinical recovery and prevent readmission, we recommend the following Recent data from 46 cases on 6 month follow-up suggests a reduction in functional exercise capacity, but few long-term organ specific morbidities after recovery [86] . We continue to recommend close follow-up. Follow-up visits should be scheduled with the child's primary care provider within 24 -72 hours after discharge. Rheumatology follow-up at our institution is usually 1 -2 weeks after discharge and includes repeat of pertinent laboratory markers, and if corticosteroids were used, a slow tapering off guided by clinical and laboratory parameters.

Cardiology follow-up will vary depending on degree of cardiac involvement, but at minimum all patients should follow up 4 weeks after discharge [27] . We have children follow-up with infectious disease to review similarities to KD convalescence (such as peeling rash or reactive thrombocytosis) and for consideration of measurement of convalescent titers for any alternative diagnoses. These visits typically coincide with cardiology clinic visits. Other follow-up visits are dependent on the child's clinical course. There is little data to guide the optimal timing for vaccination after recovery from a case of MIS-C. Currently, the CDC suggests considering delaying vaccination until three months after MIS-C diagnosis if full recovery has been achieved Our group agrees with the majority of the current recommendations proposed by the panel from the American College of Rheumatology [27] . Our approach differs slightly in a few areas. With the recent data supportive of improvements in fever, cardiac function, and hospital course [50] we have treated all cases of suspected MIS-C warranting hospital admission with IVIG and methylprednisolone. We are likely to continue this practice except in cases with specific contraindications or a strong suspicion of alternative acute infections. For cases that present with a wider differential that includes invasive bacterial disease, initiating treatment with IVIG alone or IVIG with low dose methylprednisolone should be considered. In severe presentations including those with shock, we would start with high doses of methylprednisolone (10-30 mg/kg/day) and have a low threshold to add anakinra early in the course.

As cases of MIS-C continue to temporally follow local disease spread, we advise continued vigilance in the approach to febrile children with recent history of or close exposure to SARS-CoV-2. Vaccination of persons of all ages, including children, is necessary to prevent continuous spread and should, in effect, prevent MIS-C. Rare cases of transient myocarditis in adolescents and young adults following the second dose of mRNA-based vaccines do not appear to have symptomatic overlap with MIS-C, but details are not yet published. Despite the rarity of J o u r n a l P r e -p r o o f these reports, they may affect the uptake of vaccine in pediatric populations. The diagnosis of MIS-C cases will become even more challenging as vaccination and natural immunity lead to lower circulating rates of SARS-CoV-2 infection as cases are likely to be more sporadic.

MIS-C continues to be a highly concerning diagnosis in those recently infected with SARS-CoV-2. Febrile children presenting with cardiac dysfunction, symptoms overlapping KD or significant GI complaints warrant a thorough screen in emergency departments, urgent care centers, and outpatient pediatric or family medicine practices. An increased index of suspicion and discussion regarding higher level of care (transferring to pediatric tertiary care centers or to intensive care) continue to be recommended. As outlined herein, a broad initial approach with a multidisciplinary team for those meeting the case definition is crucial for successful outcomes.

This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Guideline was created following the CDC case definition, published cases, and other guidelines with input from emergency medicine physicians, hospitalists, intensivists, and specialists in the areas of critical care, infectious diseases, cardiology, rheumatology, and hematology. Screening labs we recommend in our hospital are underlined. "Set 1 subset B" labs are followed in more severe cases. Mpred = Methylprednisolone. 

Clinical and epidemiological features of 36 children with J o u r n a l P r e -p r o o f Journal Pre-proof coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study

Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic

Multisystem Inflammatory Syndrome in Children in New York State

Multisystem inflammatory syndrome in pediatric COVID-19 patients: a meta-analysis

Management of Multisystem Inflammatory Syndrome in Children Associated With COVID-19: A Survey From the International Kawasaki Disease Registry

A Systematic Review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV

The Natural History of Severe Acute Respiratory Syndrome Coronavirus 2-Related Multisystem Inflammatory Syndrome in Children: A Systematic Review

COVID-19 associated Multisystem Lancet

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease

Multisystem inflammatory syndrome in children (MIS-C): Report of the clinical and epidemiological characteristics of cases in Santiago de Chile during the SARS-CoV-2 pandemic

Multisystem inflammatory syndrome in children related to COVID-19: A New York City experience

Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study

Pediatric Inflammatory Multisystem Syndrome (PIMS) Did Occur in Poland during Months with Low COVID

Preliminary Results of a Nationwide Register

Multisystem inflammatory syndrome J o u r n a l P r e -p r o o f Journal Pre-proof associated with SARS-CoV-2 infection in 45 children: a first report from Iran

Racial and/or Ethnic and Socioeconomic Disparities of SARS-CoV-2 Infection Among Children

SARS-CoV-2 Positivity Rates Among Children of Racial and Ethnic Minority Groups in Mississippi

Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19

Socioeconomic and Racial/Ethnic Disparities in Multisystem Inflammatory Syndrome

Reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection -United Kingdom and United States

Multisystem Inflammatory Syndrome in Adults

Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2

Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation

Definitive pathognomonic signs and symptoms of paediatric neurological COVID-19 are still emerging

How COVID-19 Affects the Brain

COVID-19-Associated Multisystem Inflammatory Syndrome in Children -United States

Acute Heart Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-CoV-2 Pandemic

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Consequences of the COVID-19 pandemic on J o u r n a l P r e -p r o o f Journal Pre-proof admissions to general hospital psychiatric wards in Italy: Reduced psychiatric hospitalizations and increased suicidality

Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States

Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study

The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

ESDN, a novel neuropilin-like membrane protein cloned from vascular cells with the longest secretory signal sequence among eukaryotes, is up-regulated after vascular injury

Multisystem Inflammatory Syndrome in Children (MIS-C), a Post-viral Myocarditis and Systemic Vasculitis-A Critical Review of Its Pathogenesis and Treatment

Acute Appendicitis in Multisystem Inflammatory Syndrome in Children With COVID-19

Covid-19 Commission of Accademia Nazionale dei

COVID-19 vaccines: where we stand and challenges ahead

Current advances in the development of SARS-CoV-2 vaccines

Performance assessment of 11 commercial serological tests for SARS-CoV-2 on hospitalised COVID-19 patients

Five Commercial Immunoassays for SARS-CoV-2 Antibody Determination and Their Comparison and Correlation with the Virus Neutralization Test

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison

Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents

Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in

Multisystem Inflammatory Syndrome in Children

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients with COVID-19. medRxiv

Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*

Features of Intestinal Disease Associated With COVID-Related Multisystem Inflammatory Syndrome in Children

Gastrointestinal Symptoms as a Major Presentation Component of a Novel Multisystem Inflammatory Syndrome in Children

SARS-CoV-2 productively infects human gut enterocytes

A Case of Multisystem Inflammatory Syndrome in Children Mimicking Acute Appendicitis in a COVID-19 Pandemic Area

Multisystem inflammatory syndrome in SARS-CoV-2 infection mimicking acute appendicitis in children

Acute appendicitis in four children with SARS-CoV-2 infection

Rate of Pediatric Appendiceal Perforation at a Children's Hospital During the COVID-19 Pandemic Compared With the Previous Year

Acute Appendicitis Mimicking Multisystem Inflammatory Syndrome in Children: Case Report and Review of the Literature

Mistaken MIS-C: A Case Series of Bacterial Enteritis Mimicking MIS-C

Acute Hepatitis Is a Prominent Presentation of the Multisystem Inflammatory

Clinical Manifestations of Kawasaki Disease Shock Syndrome

Interim Guidance: Return to Sports and Physical Activity

COVID-19 and multisystem inflammatory syndrome in children: A systematic review and meta-analysis

Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease

Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children

Therapeutic Plasma Exchange in Children With Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience

Guidelines from the Extracorporeal Life Support Organization (ELSO)

Confirmation of the high cumulative J o u r n a l P r e -p r o o f Journal Pre-proof incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness

Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series

Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review

IL-1 blockade in autoinflammatory syndromes

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm

High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant

The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study